close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

50.92 -0.03 (-0.05%)
Streaming Delayed Price Updated: 10:08 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
QIAGEN Completes Acquisition of Verogen, Strengthening Leadership in Human ID / Forensics With NGS Technologies
From QIAGEN
Via Business Wire
News headline image
QIAGEN and Helix Launch Exclusive Partnership to Advance Next-Generation Sequencing Companion Diagnostics in Hereditary Diseases
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q3 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
IGI Inex Holding (UK) Becomes Strategic Investor in Quantumrock, Cementing Partnership Between Leading Global Investment Group and AI Asset Tech Frontrunners
Via ACCESSWIRE
News headline image
QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Issues 2021 Sustainability Report
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Proposes Expansion of Supervisory Board
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR System
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN exceeds outlook for Q1 2022, delivers strong 14% CER sales growth from non-COVID products and increases full-year outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to release results for Q1 2022 and hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Reaches Milestone With 100 Million QuantiFERON Tests Used to Detect TB
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Announces 20-F Annual Report Filing for 2021 Results
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN beats outlook for fourth quarter and full-year 2021, delivers 22% CER full-year sales growth from non-COVID products
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN’s Commitment to LGBTQ+ and Gender Equality Recognized by Human Rights Campaign and Bloomberg Indexes
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Completes U.S. Federal Contract to Equip Local Public Health Authorities with QIAcuity Digital PCR System for COVID-19 Surveillance
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today